Senhwa Biosciences Inc. was established in 2012 and listed on the Taipei Exchange (TPEx) on April 24, 2017. The company aims to transform the model for new drug development by focusing on human efficacy. Senhwa believes that its dedication to science and rigorous processes will enable Senhwa to achieve remarkable milestones.
Senhwa has a strong Management Team with a proven track record in developing new drugs and targeted agents. Headquartered in Taiwan, with a vital operational base in San Diego, California, Senhwa is well positioned to oversee the development of their compounds by collaborating with a diverse range of global investigators and service providers. Clinical trials are ongoing or planned for Australia and the US and our service providers work from their bases in North America, Asia, Australia and Europe.
Senhwa Biosciences Inc. identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated. Our central philosophy is to unearth validated targets or therapies that could significantly improve treatment, but have not yet been properly exploited. As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through to clinical Proof-of-Concept.